Phase 2 study of romiplostim N01 to prevent chemoradiotherapy-induced thrombocytopenia in postoperative high-risk endometrial cancer

Phase 2, open-label, single-arm trial of romiplostim in endometrial cancer (EC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Proportion of patients who develop a platelet count <75 × 10^9/L within 3 weeks after initiation of concurrent chemoradiotherapy. Planned start Oct 2026; status: not yet recruiting.